The current methods of assessing breast cancer tissues are largely morphology based and only a small set of biomarkers consisting of estrogen receptors (ER), progesterone receptors (PR), Her2neu protein or HER2neu gene amplification, and to limited extent, Ki-67, a marker of cell proliferation, are in routine clinical use. This evidence concerns the gene PGR and breast carcinoma.